The reiteration of an Outperform rating combined with an increased price target by a reputable analyst like Francois Brisebois suggests a strong bullish sentiment towards Tarsus Pharmaceuticals. This is likely to positively influence investor perception and could lead to a short-term increase in the stock price, as market participants may adjust their positions based on this new target and rating.